Helix BioPharma Corp. Appoints Dr. Markus Loeffler as Chief Medical Officer

Vancouver, British Columbia — August 17, 2026 — Leads & Copy — Helix BioPharma Corp. announced the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO). Dr. Loeffler’s appointment coincides with the company’s transition into a more execution-driven phase of clinical development, with multiple programs nearing significant regulatory and clinical milestones.

In his new role, Dr. Loeffler will oversee the strategy and execution of Helix’s clinical programs. This includes the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab for first-line non-small cell lung cancer (NSCLC). He will also guide LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation.

“I’ve had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix. “He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic.”

Dr. Loeffler is a physician-scientist and biotechnology executive with over three decades of leadership experience in oncology drug development. His background includes advancing oncology therapeutics, such as small molecules, biologics, antibody-drug conjugates (ADCs), radiopharmaceuticals, and immunotherapies, from early clinical development through Phase III and regulatory approval. Previously, he held senior clinical development and CMO positions at prominent biotechnology and pharmaceutical firms including Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. Dr. Loeffler was also instrumental in leading the pivotal Phase III clinical program for Lutathera®, which later received approval for specific gastroenteropancreatic neuroendocrine tumors.

“I’m excited to join Helix at such an important stage in its evolution,” said Dr. Loeffler. “The Company’s pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers.”

Helix BioPharma Corp. is a clinical-stage oncology company dedicated to developing therapies for underserved patient populations facing difficult-to-treat cancers. The company's pipeline features L-DOS47, a clinical-stage antibody-enzyme conjugate intended for use as a combination therapy for NSCLC. Other pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator targeting post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.

Helix BioPharma's common shares are traded on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCF), and listed on the Frankfurt Stock Exchange (FWB: HBP0).

Source: Helix BioPharma Corp.